Navigation Links
Scientists learn more about how kidneys fail and how new drugs may intervene
Date:11/16/2010

he study's first author. The study provides more scientific evidence that the new endothelin A receptor antagonists may be the first class of drugs to fit that bill, said Saleh, noting that his native Egypt, like the United States, has an increasing problem with diabetes.

The positive results were achieved without affecting blood pressure, the scientists noted. Endothelin receptor antagonists are known to have health benefit but precisely why was an unknown, said Pollock, corresponding author on the study. "A lot of people thought they just lower blood pressure and anything that lowers blood pressure is going to make your kidneys feel better," he said.

Endothelin 1 has A and B receptors and whether the peptide hurts or helps generally depends on which receptor it activates. The B receptor is considered the good guy, helping the kidney eliminate excess sodium, for example. The A receptor is generally considered a trouble maker that interferes with sodium excretion, constricts blood vessels and promotes inflammation.

The MCG scientists want to compare A inhibitors to another new class of drugs that blocks both the A and B receptors.


'/>"/>

Contact: Toni Baker
tbaker@mcg.edu
706-721-4421
Medical College of Georgia
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
2. Scientists identify novel inhibitor of human microRNA
3. Argonne scientists peer into heart of compound that may detect chemical, biological weapons
4. MU scientists go green with gold, distribute environmentally friendly nanoparticles
5. Scientists identify gene that may contribute to improved rice yield
6. Scientists discover why a mothers high-fat diet contributes to obesity in her children
7. MU scientists see how HIV matures into an infection
8. Earth scientists keep an eye on Texas
9. Thinking it through: Scientists call for policy to guide biofuels industry toward sustainability
10. Scientists identify a molecule that coordinates the movement of cells
11. Scientists Find new migratory patterns for Mediterranean and Western Atlantic bluefin tuna
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scientists learn more about how kidneys fail and how new drugs may intervene
(Date:8/27/2014)... the greatest risk to Europe based upon a proxy ... researchers using a ,big data, approach to scientific research. ... and Global Health ranked the top 100 pathogens affecting ... a system which, they believe, will help governments across ... of infectious diseases, including as a result of climate ...
(Date:8/27/2014)... 2014 /PRNewswire-iReach/ -- The IEEE Engineering in Medicine and ... Annual International Conference (EMBC,14), this year being held at ... Chicago, Illinois , from Tuesday, August 26 through ... and industry professionals in science, medicine, and engineering are ... This year,s conference theme is ...
(Date:8/27/2014)... is available in German . ... the most common inherited disease affecting the peripheral nervous ... Max Planck Institute of Experimental Medicine and University Medical ... cells is impaired in rats with the disease. These ... known as myelin, which facilitates the rapid transfer of ...
Breaking Biology News(10 mins):Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 3Potential therapy for incurable Charcot-Marie-Tooth disease 2
... young scientists have received postdoctoral fellowships from the National ... they conduct research with the eventual aim of protecting ... mentorship from a faculty member at their home institution, ... research teams. This allows them to interact with some ...
... from a pivotal, large-scale Phase III trial, published online ... , show that the RTS,S malaria vaccine candidate can ... immunization with a control vaccine, infants (aged 6-12 weeks ... episodes of both clinical and severe malaria and had ...
... Nearly 3,000 insect scientists are expected to attend Entomology 2012, ... this November in Knoxville, TN. Members of the media who ... press pass. WHEN: November 11-14, 2012 ... WHAT: Entomology 2012 is the 60th Annual ...
Cached Biology News:Space research institute awards postdoctoral fellowships to 4 scientists 2RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants 2RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants 3RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants 4
(Date:8/27/2014)... Aug. 27, 2014 Guggenheim Securities, the investment ... announced the hiring of veteran equity analyst Charles "Tony" ... Mr. Butler will focus on the biotech/biopharma sector. ... wealth of experience and a broad network of relationships ... Managing Director and Head of Equities at Guggenheim Securities. ...
(Date:8/27/2014)...  ARCH Venture Partners, one of the largest ... of seed and early-stage advanced technology companies, today ... more than $400 million in subscriptions. ARCH Venture ... by more than $150 million. "The ... potential of our approach to finding and funding ...
(Date:8/27/2014)... City, OR (PRWEB) August 27, 2014 ... Report, “Consolidation continues to reshape the look and feel ... nutrition. Consumer demand for higher-quality ingredients will push for ... North American market have experienced strong market growth in ... ethical attributes in their food and cosmetics to fit ...
(Date:8/26/2014)...  NeuroSigma, Inc., a Los Angeles ... today announced that it has filed a registration statement ... Commission relating to a proposed initial public offering of ... offered and the price range for the proposed offering ... will act as the book-running manager for the proposed ...
Breaking Biology Technology:Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3
... sizes and shapes, scientists now understand how they lose ... weighing any single atom. Such ultrasensitive measurements could ... and diagnostics, enabling the detection of minuscule disease-causing agents ... level. Researchers are interested in nanosized materials because ...
... ... , ... CA (Vocus) - GreenHouse announced today that on July 30, 2009 it will introduce ... a high performance ethanol fuel for cars. The first installation of the E-Fuel ...
... , , , ... Calif. and LONDON, July 27 Amgen (Nasdaq: AMGN ... companies will share commercialization of Amgen,s monoclonal antibody denosumab for postmenopausal ... product is approved in these countries. Amgen will commercialize the ...
Cached Biology Technology:1 nano-step closer to weighing a single atom 2GreenHouse Debuts the World's First E-Fuel MicroFuelerTM in Los Angeles 2GreenHouse Debuts the World's First E-Fuel MicroFuelerTM in Los Angeles 3Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 2Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 3Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 4Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 5Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 6Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 7